Group 1 - The eighth China International Import Expo opened on November 5, showcasing Gilead's commitment to creating a healthier world with a 500 square meter exhibition space [1] - Gilead presented two Asia debut products: long-acting HIV pre-exposure prophylaxis drug Lenacapavir and a new drug for primary biliary cholangitis (PBC) Seladelpar, along with 13 innovative drugs launched in China [1] - Gilead's global vice president and general manager for China, Jin Fangqian, emphasized the company's accelerated development in China, highlighting the transformation of several "Expo babies" from exhibits to commercial products [1] Group 2 - Gilead plans to sign nearly ten cooperation projects at the expo to enhance the accessibility of innovative drugs and promote standardized diagnosis and treatment [2] - Jin Fangqian expressed confidence in Gilead's long-term development in China, citing the country's efforts in expanding openness, strengthening intellectual property protection, and optimizing the business environment [2] - The company aims to support the high-quality development of China's healthcare sector and contribute to the "Healthy China 2030" goal [2]

Core Insights - The China International Import Expo (CIIE) has become a significant platform for accelerating the availability of innovative drugs to Chinese patients, as highlighted by Novartis and Gilead Sciences [1][2] Group 1: Novartis - Novartis has showcased its innovative cardiovascular and renal treatment solutions at the CIIE, marking its eighth consecutive year of participation [1] - Several innovative drugs in the cardiovascular and renal fields have transitioned from exhibition to approval, benefiting from the spillover effects of the CIIE [1] Group 2: Gilead Sciences - Gilead Sciences has introduced two products at the CIIE, including the long-acting HIV prevention drug Lenacapavir and a new drug for primary biliary cholangitis, marking their Asian debut [1] - The company is actively advancing local R&D with 16 ongoing projects in China, including 10 in oncology and 6 in non-oncology, aiming for 90% of oncology projects to achieve global synchronization [2] - Gilead plans to sign nearly ten cooperation projects at the CIIE to enhance the accessibility of innovative drugs and promote standardized diagnosis and treatment [3]